Female reproductive system disorder
MONDO:0002263A disease involving the female reproductive system.
Also known as: disease of female reproductive system, disease or disorder of female reproductive system, disorder of female genital system, disorder of female reproductive system, female reproductive disease, female reproductive system disease, female reproductive system disease or disorder, female reproductive system disorder
3079 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1281 trials in this tab.
-
DNA vaccine aims to train immune system against HPV-Linked cervical lesions
⭐️ VACCINE ⭐️ Recruiting nowThis phase 1 trial tests a DNA vaccine designed to target HPV16, a virus that can cause high-grade cervical lesions (CIN2/3). The vaccine is given by injection into the muscle followed by a mild electrical pulse to help cells take up the DNA. The study includes both HIV-negative …
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 04, 2026 00:00 UTC
-
New vaccine aims to boost immunity against advanced cervical cancer
⭐️ VACCINE ⭐️ Recruiting nowThis study is testing a new vaccine called PVX7 in 32 women with advanced cervical cancer who have finished their main treatment (surgery, radiation, or chemo). The goal is to see if the vaccine is safe and can boost the body's immune response against HPV, the virus that causes c…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 03, 2026 00:00 UTC
-
New HPV vaccine trial aims to protect kids and teens from cancer
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a bivalent HPV vaccine in healthy infants (9 months), toddlers (15 months), children (2-5 years), and unmarried young women (15-20 years) in Ghana. Researchers want to see if the vaccine is safe and triggers a strong immune response, especially when given alongsi…
Phase: PHASE2 • Sponsor: International Vaccine Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:34 UTC
-
New hope for advanced cervical cancer: adding immunotherapy before standard care
Disease control Recruiting nowThis phase III trial tests whether giving an extra round of chemotherapy and immunotherapy (pembrolizumab) before the usual chemoradiation can help people with high-risk, locally advanced cervical cancer live longer without the cancer growing. About 336 participants will be rando…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered immune cells take on metastatic tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control Recruiting nowThis phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase: PHASE1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for endometrial cancer: Mo-Rez drug faces chemo in major trial
Disease control Recruiting nowThis large Phase 3 study tests a new drug called mocertatug rezetecan (Mo-Rez) against standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. About 600 participants will be randomly assigned to receive either Mo-…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug duo aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThis phase 3 trial tests whether adding trastuzumab deruxtecan (T-DXd) to standard bevacizumab maintenance therapy can delay cancer progression better than bevacizumab alone in people with HER2-expressing advanced ovarian cancer. About 582 adults whose cancer has a specific prote…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for tough endometrial cancer: Four-Drug combo trial launches
Disease control Recruiting nowThis Phase III trial tests whether adding the drug bevacizumab to a standard chemotherapy plus immunotherapy regimen can help people with a specific type of advanced or recurrent endometrial cancer (pMMR, TP53 mutated). About 255 participants will be randomly assigned to one of t…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo aims to outsmart recurrent ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding olaparib to selumetinib works better than selumetinib alone for women with recurrent or persistent ovarian or endometrial cancers that have a RAS pathway mutation. Selumetinib blocks enzymes that help cancer grow, while olaparib stops cance…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug DM002 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…
Phase: PHASE1, PHASE2 • Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New Triple-Drug attack on cervical cancer enters final testing
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (sac-TMT) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) helps people with metastatic cervical cancer live longer. About 1,000 participants whose cancer has sprea…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can hormone patches and pills help teens with ovarian failure?
Disease control Recruiting nowThis study looks at how hormone replacement therapy (HRT) affects adolescents aged 11-19 with premature ovarian insufficiency (POI), a condition where ovaries stop working before age 40. Participants receive estrogen patches and progesterone pills over 2 years, with regular check…
Phase: PHASE3 • Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called BMS-986488, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 437 adults w…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug infusion targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo aims to shrink HER2-Positive tumors
Disease control Recruiting nowThis study tests whether adding palbociclib to neratinib works better than neratinib alone for people with HER2-positive solid tumors (excluding breast cancer). Both drugs block signals that help cancer cells grow. The trial enrolls 70 adults with advanced or recurrent gynecologi…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goal…
Phase: PHASE1 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New experimental drug BMS-986500 enters first human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Hormone showdown: which progestin best tames uterine cancer before surgery?
Disease control Recruiting nowThis study compares two hormone drugs (megestrol acetate and micronized progesterone) in 140 women with endometrial cancer or precancer. Participants take one of the drugs for a short time before their scheduled surgery. Researchers will measure how well each drug slows cancer ce…
Phase: PHASE2 • Sponsor: New Mexico Cancer Research Alliance • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New immune cell therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New targeted pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Immune cells retrained to hunt ovarian cancer in new trial
Disease control Recruiting nowThis phase 1 trial investigates a new treatment for advanced ovarian cancer that has stopped responding to platinum chemotherapy. The therapy uses a patient's own immune cells, called T cells, which are genetically modified in a lab to recognize and attack a protein called TAG72 …
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for drug-resistant ovarian cancer: experimental pill targets tumor weakness
Disease control Recruiting nowThis study tests an experimental drug called azenosertib (ZN-c3) in people with a specific type of ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum chemotherapy. The drug aims to shrink or control tumors by blocking a protein that cancer cells nee…
Phase: PHASE2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New study tests hormone combo to boost IVF success in adenomyosis patients
Disease control Recruiting nowThis study tests whether a two-month hormone pretreatment (GnRH agonist plus letrozole) before standard frozen embryo transfer can improve live birth rates in women with adenomyosis. About 222 participants will be randomly assigned to either the new regimen or standard care. The …
Phase: NA • Sponsor: Mỹ Đức Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a simple surgery replace chemo for this rare Pregnancy-Related cancer?
Disease control Recruiting nowThis study compares a repeat curettage (a scraping procedure inside the uterus) against standard chemotherapy with methotrexate as the first treatment for women with low-risk gestational trophoblastic neoplasia, a rare cancer that can develop after a molar pregnancy. The goal is …
Phase: PHASE3 • Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Immune cell cocktail takes on Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests a new approach for people with platinum-resistant high-grade ovarian cancer, a type that no longer responds to standard chemotherapy. Up to 20 participants will receive their own immune cells (M-CENK) that have been trained to fight cancer, along with an …
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo trial aims to fight advanced cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill for Hard-to-Treat cancers enters first human tests
Disease control Recruiting nowThis early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…
Phase: PHASE1 • Sponsor: Degron Therapeutics Co. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Hope for Platinum-Resistant ovarian cancer: new pill takes on chemo
Disease control Recruiting nowThis Phase 3 trial tests a new oral drug, INCB123667, against standard chemotherapy in 466 people with platinum-resistant ovarian cancer that overexpresses cyclin E1. The goal is to see if the new drug can delay cancer growth or improve survival. Participants will be randomly ass…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can a mesh shield ovarian cancer patients from painful hernias?
Disease control Recruiting nowThis trial tests whether placing a surgical mesh during abdominal closure can prevent incisional hernias in women undergoing ovarian cancer surgery. It also examines if a negative pressure wound dressing reduces infection risk. Participants are randomly assigned to one of four gr…
Phase: NA • Sponsor: Hospital Vall d'Hebron • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug SLV-154 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …
Phase: PHASE1 • Sponsor: Solve Therapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Plasma zaps HPV: new hope for cervical infections?
Disease control Recruiting nowThis study tests whether a non-invasive physical plasma treatment can clear HPV infections from the cervix. About 50 adults with HPV will receive the treatment, and researchers will check if the virus is gone afterward. The goal is to find a new way to prevent cervical cancer cau…
Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug BNT323 faces chemo in phase 3 trial
Disease control Recruiting nowThis Phase 3 trial tests whether the drug BNT323 (trastuzumab pamirtecan) works better than standard chemotherapy for people with recurrent endometrial cancer that expresses HER2. About 480 participants will be split into two groups based on their HER2 levels. The study measures …
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a common heart drug boost ovarian cancer treatment?
Disease control Recruiting nowThis phase 2 trial tests whether adding propranolol, a widely used beta-blocker, to standard chemotherapy before surgery can improve outcomes for women with advanced high-grade serous ovarian cancer. Participants receive propranolol pills alongside paclitaxel and carboplatin, fol…
Phase: PHASE2 • Sponsor: Bai-Rong Xia • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New surgery comparison aims to reduce bleeding in dangerous placenta condition
Disease control Recruiting nowThis study compares three surgical techniques for managing placenta accreta, a condition where the placenta grows too deeply into the uterine wall. The goal is to find which method causes the least blood loss during delivery. The trial will enroll 42 pregnant women with this cond…
Phase: NA • Sponsor: Assiut University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug ALE.P02 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus that have spread or cannot be removed. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 170 adult…
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug azenosertib takes on Chemo-Resistant ovarian cancer in phase 3 trial
Disease control Recruiting nowThis phase 3 study tests whether a new drug called azenosertib works better than standard chemotherapy for people with a specific type of ovarian cancer that no longer responds to platinum-based treatments. The trial enrolls 420 women whose tumors have a high level of a protein c…
Phase: PHASE3 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug XMT-1660 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can cervical cancer patients stop immunotherapy early? new study investigates
Disease control Recruiting nowThis study follows 261 people with persistent, recurrent, or metastatic cervical cancer who are taking pembrolizumab (Keytruda) with or without bevacizumab (Avastin). Some participants may choose to stop pembrolizumab early if their tumor shrinks or disappears, while others conti…
Phase: PHASE4 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New cocktail of chemo and immunotherapy aims to fight advanced ovarian cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of three drugs (carboplatin, paclitaxel, and pembrolizumab) given before surgery to shrink tumors in women with newly diagnosed stage III or IV ovarian cancer. After surgery, participants receive two maintenance drugs (olaparib and pemb…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New mRNA vaccine aims to stop ovarian Cancer's return
Disease control Recruiting nowThis early-stage trial tests a new mRNA cancer vaccine called CryptiVax-1001 in 50 women with advanced ovarian cancer. The vaccine is designed to train the immune system to recognize and attack cancer cells, potentially delaying or preventing the cancer from coming back. The main…
Phase: PHASE1 • Sponsor: Epitopea Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Own stem cells may shield bone marrow during ovarian cancer chemo
Disease control Recruiting nowThis trial investigates whether giving back a patient's own blood stem cells after chemotherapy can help their bone marrow recover faster. The study includes women aged 18–60 with recurrent or metastatic ovarian cancer who are scheduled for chemotherapy. The goal is to reduce sev…
Phase: NA • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay
Disease control Recruiting nowThis Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill targets Hard-to-Treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…
Phase: PHASE1 • Sponsor: Kestrel Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug CR-001 enters human trials
Disease control Recruiting nowThis study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Crescent Biopharma, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThis phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase trial is testing the safety and best dose of two drugs, M1774 and ZEN-3694, given together to patients with recurrent ovarian or endometrial cancer. The drugs work by blocking enzymes that cancer cells need to grow. The study aims to find a dose that is safe and …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: enhertu studied in 20+ tumor types
Disease control Recruiting nowThis study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could storing your own stem cells shield bone marrow during cancer treatment?
Disease control Recruiting nowThis trial investigates whether collecting and storing a patient's own blood stem cells before chemoradiotherapy, then re-infusing them after treatment, can help rebuild healthy blood cells faster. The study includes 40 women with cervical cancer who are scheduled for chemoradiot…
Phase: NA • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat endometrial cancer
Disease control Recruiting nowThis early-phase study tests a combination of three drugs (avutometinib, defactinib, and everolimus) in people with recurrent endometrial cancer that has specific genetic changes in the RAS pathway. The main goal is to find a safe dose and understand side effects. About 31 partic…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug could keep cervical cancer away after chemoradiation
Disease control Recruiting nowThis phase 3 trial is testing an immunotherapy drug called volrustomig in 800 women with high-risk locally advanced cervical cancer who have finished chemoradiation. The goal is to see if volrustomig can keep the cancer from coming back or improve survival compared to a placebo. …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug aimed at folate receptor shows promise for tough endometrial cancer
Disease control Recruiting nowThis phase 2 trial tests a drug called mirvetuximab soravtansine in 50 women with a specific type of endometrial cancer that has come back or won't go away. The drug targets a protein called folate receptor alpha, which is often found on these cancer cells. Researchers want to se…
Phase: PHASE2 • Sponsor: Alessandro Santin • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New Antibody-Drug combo takes aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for ovarian cancer: targeted drug combo enters Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial tests mirvetuximab soravtansine, a targeted drug, combined with standard chemotherapy (carboplatin) or bevacizumab in 400 people with a specific type of ovarian cancer (FRα-positive). The study aims to find the best dose and combination to shrink tumors and con…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New study targets ovarian cancer in black women: could genes affect treatment?
Disease control Recruiting nowThis study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Researchers want to see if genetic or environmental factors affect side effects and how the drug works. About 70 women will take nirapa…
Phase: PHASE4 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug XTX301 takes on advanced cancers in first human trial
Disease control Recruiting nowThis study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Triple-Drug cocktail aims to boost ovarian cancer surgery success
Disease control Recruiting nowThis phase 2 trial is testing a combination of three drugs—ipalotinib, sunitinib, and olaparib—given before surgery to people with a specific type of advanced ovarian cancer (HRD-positive). The goal is to shrink tumors enough to allow complete removal during surgery. The study wi…
Phase: PHASE2 • Sponsor: Bai-Rong Xia • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail aims to outsmart aggressive uterine cancer
Disease control Recruiting nowThis phase 3 trial is testing whether a targeted drug (trastuzumab deruxtecan) combined with immunotherapy (rilvegostomig or pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced or recurrent endometrial cancer that has a specific prot…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to control rare ovarian cancer
Disease control Recruiting nowThis study tests whether combining two drugs, dostarlimab and LB-100, can help control ovarian clear cell carcinoma. About 21 adults with recurrent disease will receive the drugs by vein. The main goal is to check safety and see if the tumors shrink or stop growing.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New immune drug PHST001 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…
Phase: PHASE1 • Sponsor: Pheast Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take on Hard-to-Treat cervical cancer
Disease control Recruiting nowThis study tests a new treatment for people with advanced or recurrent cervical cancer linked to high-risk HPV. The treatment uses specially engineered immune cells (CC-EIEs) designed to target and attack the cancer. Participants receive several infusions of these cells, and rese…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo trial targets Hard-to-Treat breast and ovarian cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called AZD8421, alone or with other cancer drugs, in people with advanced ER+ breast cancer or high-grade ovarian cancer. The study aims to find safe doses and see if the drug can shrink tumors. About 564 women aged 18 and older will t…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New surgery aims to shield fertility in women undergoing pelvic radiation
Disease control Recruiting nowThis phase I trial tests a surgical procedure called utero-ovarian transposition (UOT) to temporarily move the uterus, ovaries, and fallopian tubes out of the radiation field in women aged 18-40 with pelvic cancers. The goal is to preserve fertility and ovarian function during wh…
Phase: NA • Sponsor: University of South Florida • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug hopes to shrink tumors in patients out of options
Disease control Recruiting nowThis study tests a new drug called BI 3820768 in adults with advanced germ cell tumors, endometrial cancer, or ovarian cancer who have run out of treatment options. The drug aims to help the immune system fight cancer. Researchers will give increasing doses to find a safe amount …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
One-Week radiation plus chemo for endometrial cancer: a feasibility trial
Disease control Recruiting nowThis early-phase study tests whether a short course of radiation (1 week instead of the usual 5) combined with standard chemotherapy (carboplatin and paclitaxel) is practical for people with stage III endometrial cancer. The trial will enroll 28 participants and aims to see if mo…
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Cancer drug niraparib gets Long-Term safety check in extension trial
Disease control Recruiting nowThis study offers continued access to niraparib, a daily oral cancer drug, for up to 37 patients with ovarian or breast cancer who have already completed a prior niraparib trial and are still benefiting. The main goal is to monitor long-term safety, including side effects and cha…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy for endometrial cancer tested in Real-World setting
Disease control Recruiting nowThis study is tracking the safety and effectiveness of durvalumab (with or without olaparib) in about 50 Korean patients with endometrial cancer who are already prescribed these drugs. Researchers will follow participants for up to 12 months to see how well the treatment works in…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental CAR t therapy targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study is testing a new treatment called SynKIR-110 for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has spread or come back. The treatment involves taking a patient's own immune cells, engineering them in a lab to better recognize a…
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Weekly shot could replace daily growth hormone for kids
Disease control Recruiting nowThis phase 3 trial compares a once-weekly growth hormone injection (lonapegsomatropin) to a daily one (somatropin) in 186 prepubertal children with growth failure due to Turner syndrome, SHOX deficiency, being small for gestational age, or idiopathic short stature. The goal is to…
Phase: PHASE3 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Hard-to-Treat cancers: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a drug cocktail slash deaths from TB of the brain?
Disease control Recruiting nowThis Phase III trial in sub-Saharan Africa tests whether giving higher doses of rifampicin plus linezolid, along with aspirin, can reduce deaths from tuberculous meningitis (TBM) in both HIV-positive and HIV-negative people. About 768 adolescents and adults will receive either th…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immune cells take on ovarian cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing whether specially engineered immune cells (OC-CTLs) can safely fight ovarian cancer. Twenty women with advanced-stage disease will receive 2 to 4 infusions of these cells. Researchers will monitor side effects and check if tumors shrink or stabil…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Platinum-Resistant ovarian cancer: experimental drug ubamatamab enters phase 2 trials
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called ubamatamab, alone or combined with other cancer drugs, in 220 people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The study aims to see how…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental cancer drug enters human testing
Disease control Recruiting nowThis early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat cervical cancer
Disease control Recruiting nowThis trial investigates whether specially engineered immune cells (CAR-T cells) can safely treat advanced or recurrent cervical cancer. The cells are designed to recognize and attack cancer cells that carry certain markers like GD2 or Mesothelin. The study involves 20 adults with…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New study tracks Durvalumab's Real-World impact on endometrial cancer
Disease control Recruiting nowThis study is collecting real-world data from 150 women in Germany with advanced or recurrent endometrial cancer. Participants receive standard first-line treatment with chemotherapy plus durvalumab, followed by maintenance therapy with durvalumab alone or with olaparib. The goal…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill targets Hard-to-Treat cancers with specific gene mutation
Disease control Recruiting nowThis study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…
Phase: PHASE1, PHASE2 • Sponsor: Ensem Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy duo shows promise for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis phase II trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than nivolumab alone for women with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). About 81 participants will receive either the combinatio…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Antibody-Drug conjugate enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Targeted pill aims to halt recurrent uterine cancer
Disease control Recruiting nowThis phase 2 trial tests the drug afatinib in 50 women with a rare, aggressive uterine cancer (HER2-positive uterine serous carcinoma) that has persisted or returned. Afatinib is a daily pill that blocks a protein driving cancer growth. The main goal is to see if it can keep the …
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
Disease control Recruiting nowThis phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Exercise and diet counseling may help cancer patients finish chemo
Disease control Recruiting nowThis study tests whether a program of exercise and nutrition counseling helps women with ovarian or endometrial cancer stick with their chemotherapy plan. About 200 women who are about to start chemotherapy will be randomly assigned to either receive weekly coaching sessions on p…
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail aims to outsmart resistant uterine cancer
Disease control Recruiting nowThis phase 2 trial tests whether combining hormone therapy (letrozole) with a targeted drug (abemaciclib), and possibly adding metformin or gedatolisib, can control estrogen-receptor-positive endometrial cancer that has returned or spread. The study enrolls adults with this cance…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis early-stage trial is testing a new treatment called GB-5267 for people with ovarian cancer that no longer responds to platinum-based chemotherapy. GB-5267 is a type of immune cell therapy (CAR T cell) that has been engineered to better target cancer cells and includes an ext…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Supercharged immune cells take on cancer in new trial
Disease control Recruiting nowThis study tests whether specially engineered immune cells (EIE) can safely fight cancer. Researchers take a patient's own immune cells, modify them to target tumor-related markers, and infuse them back. The trial involves 100 people with various cancers whose tumors show specifi…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to restart periods in women with exercise-related amenorrhea
Disease control Recruiting nowThis study tests an experimental drug called mibavademab in 34 women with Functional Hypothalamic Amenorrhea (FHA), a condition where periods stop due to stress or intense exercise. The goal is to see if the drug can help the body produce the hormones needed for ovulation and imp…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo aims to outsmart Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs—vismodegib and atezolizumab—in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the combination is safe and can shrink tumor…
Phase: PHASE2 • Sponsor: Ronald Buckanovich • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Personalized treatment for early water breaking could extend pregnancy safely
Disease control Recruiting nowThis trial investigates whether using a lab test (IL-6) from amniotic fluid to guide antibiotic and steroid treatment can safely prolong pregnancy in people whose water breaks too early (preterm premature rupture of membranes, or pPROM). Participants are randomly assigned to eith…
Phase: PHASE3 • Sponsor: The Central and Eastern European Gynecologic Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Two-Drug combo targets Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests whether combining two oral drugs—ZEN003694 (a BET inhibitor) and talazoparib (a PARP inhibitor)—can shrink tumors in people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Participants must have already received a PARP inhibitor befo…
Phase: PHASE2 • Sponsor: Alexander B Olawaiye, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
Disease control Recruiting nowThis Phase 2 trial tests whether adding the experimental drug ONC201 to standard chemotherapy (paclitaxel) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 62 participants will receive the combinatio…
Phase: PHASE2 • Sponsor: Ira Winer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Breathing in chemo: new hope for lung metastases?
Disease control Recruiting nowThis early-phase study tests a chemotherapy drug (gemcitabine) given as a mist to breathe in. It is for people whose solid tumors have spread to the lungs and who have no standard treatment options. The main goal is to find the safest dose and watch for side effects. Up to 44 par…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail takes on seven tough cancers
Disease control Recruiting nowThis phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could probiotics help ovarian cancer patients on chemo?
Disease control Recruiting nowThis study tests whether taking probiotic supplements can improve the gut and vaginal microbiome in women with advanced or recurrent ovarian cancer who are receiving platinum-based chemotherapy. About 161 participants will be randomly assigned to receive either probiotics or a pl…
Phase: EARLY_PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New stitch technique may lower risks after hysterectomy
Disease control Recruiting nowThis study compares two ways to close the vaginal vault after laparoscopic hysterectomy in women with gynecologic cancers. One method uses a self-locking barbed suture, the other a traditional braided suture. The goal is to see which leads to fewer complications like cuff tears, …
Phase: NA • Sponsor: Azienda Ospedaliero-Universitaria di Parma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Platinum-Resistant ovarian cancer?
Disease control Recruiting nowThis early-stage trial tests an investigational drug called ABBV-901, alone or with a standard drug bevacizumab, in about 219 adults with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if the drug can shrink tu…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could injecting immunotherapy into lymph nodes boost cervical cancer treatment?
Disease control Recruiting nowThis early-stage trial explores whether injecting the immunotherapy drug nivolumab directly into lymph nodes before standard surgery is feasible and safe for people with cervical cancer. The study involves 12 participants and aims to see if this targeted approach can shrink tumor…
Phase: PHASE1 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets tough cancers with genetic flaw
Disease control Recruiting nowThis study tests an experimental oral drug, GSK5460025, alone or with other cancer drugs, in adults whose solid tumors have specific genetic changes (dMMR or MSI-H). The goal is to see if the drug can shrink tumors and to check its safety. About 47 people with advanced cancers th…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug IDE034 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a 3-Week radiation course beat the standard 5-Week for cervical cancer?
Disease control Recruiting nowThis study tests whether a shorter, 3-week course of radiation works as well as the standard 5-week course for women with locally advanced cervical cancer. About 396 women will be randomly assigned to one of the two schedules, both combined with chemotherapy. If the shorter sched…
Phase: NA • Sponsor: All India Institute of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New gel could tackle stubborn yeast infections
Disease control Recruiting nowThis study tests a new gel called OCF001 for treating acute yeast infections in women. About 36 women with a confirmed yeast infection will use the gel or a placebo for 7 days. Researchers will check if the infection clears up and if the gel is safe and well-tolerated.
Phase: PHASE2 • Sponsor: Sano Chemicals Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo targets advanced gynecologic cancers in early trial
Disease control Recruiting nowThis study tests a combination of two drugs, becotatug vedotin and zimberelimab, in 30 people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if the treatment can shrink tumors and control the disease. Participants must have already tried at l…
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody takes aim at Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called CTIM-76 in people with advanced ovarian, testicular, or endometrial cancers that have not responded to standard treatments. CTIM-76 is a bispecific antibody designed to attach to a protein called Claudin-6 on cancer cells and he…
Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Fish oil for tiny babies: could DHA boost brain growth in preterm infants?
Disease control Recruiting nowThis study tests whether giving DHA (a type of omega-3 fat) early to very preterm infants who are small at birth can improve head growth without causing too much fat gain. The trial will include 152 infants and measure head size and body fat at 36 weeks adjusted age. If successfu…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to shrink ovarian tumors before surgery
Disease control Recruiting nowThis study tests whether giving the targeted drug mirvetuximab soravtansine together with standard chemotherapy (carboplatin) before surgery can shrink advanced ovarian, fallopian tube, or peritoneal cancers that have a specific protein (FRα). About 140 adults with stage III or I…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immune cells trained to fight ovarian cancer in new trial
Disease control Recruiting nowThis early-phase trial tests a new type of immune cell therapy called CIML NK cells in 18 people with recurrent ovarian cancer that no longer responds to standard chemotherapy. The cells are taken from the patient, trained in a lab to better attack cancer, and then infused into t…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could your own immune cells fight ovarian cancer? tiny trial aims to find out
Disease control Recruiting nowThis early-stage trial is testing whether a patient's own tumor-fighting immune cells (called TILs) can be safely used to treat recurrent ovarian cancer. Researchers take a sample of the tumor, grow the immune cells in a lab, and then inject them back into the patient. Only 6 peo…
Phase: NA • Sponsor: Yong Wha Moon • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New PARP1 inhibitor IMP1734 enters human trials for advanced cancers
Disease control Recruiting nowThis study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…
Phase: PHASE1, PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for ovarian cancer: phase 3 trial tests targeted drug against Tough-to-Treat tumors
Disease control Recruiting nowThis large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to shrink endometrial tumors
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called ACR-368, alone or with a low dose of gemcitabine, in 350 people with high-grade endometrial cancer. A special test (OncoSignature) helps decide which treatment arm a participant joins. The main goal is to see if the drug shrink…
Phase: PHASE2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Zapping resistant tumors may extend life of cancer drugs
Disease control Recruiting nowThis study tests whether adding a precise local treatment—like focused radiation or ablation—can help people whose cancer has a few new or growing spots while on standard therapy. Participants continue their usual medication while the resistant tumors are treated directly. The go…
Phase: NA • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could 3 radiation doses beat 4 for cervical cancer?
Disease control Recruiting nowThis study compares a shorter course of brachytherapy (3 sessions) to the standard 4-session regimen for locally advanced cervical cancer. About 41 participants will receive either 3 or 4 high-dose radiation treatments based on what is feasible for them. The goal is to see if the…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug YH32364 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Experimental cell therapy targets multiple cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a sin…
Phase: PHASE1 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Fewer radiation sessions could boost cervical cancer fight
Disease control Recruiting nowThis study tests a new way to give radiation for women with advanced or bulky cervical cancer. Instead of 25 standard radiation sessions, patients get 8 larger doses along with 2 rounds of chemo. The goal is to see if this shorter, stronger approach is safe and effective at shrin…
Phase: PHASE2 • Sponsor: Denise Fabian • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for advanced endometrial cancer: targeted drug takes on chemo
Disease control Recruiting nowThis Phase 3 trial is testing a new drug called puxitatug samrotecan against standard chemotherapy in 800 people with advanced endometrial cancer that has worsened after platinum-based chemo and immunotherapy. The goal is to see if the new drug can delay cancer growth or improve …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New immune drug AZD6750 targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental immune therapy aims to tackle HPV cancers before standard care
Disease control Recruiting nowThis study tests whether a single infusion of a patient's own genetically engineered immune cells (E7 TCR-T cells) can shrink or eliminate HPV-related cancers before the patient receives standard treatment like chemo-radiation or surgery. The trial enrolls 15 adults with advanced…
Phase: PHASE1, PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New antibody drug enters first human tests for tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and to find the best dose. About 282 participants will receive…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for advanced endometrial cancer: drug combo trial launches
Disease control Recruiting nowThis study tests if the drug elacestrant, alone or with abemaciclib, can shrink or control advanced or recurrent ER+ endometrial cancer. About 75 adults who have already had chemotherapy and immunotherapy will take part. The goal is to see how well the treatment works and if it i…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug aims to stop CMV from coming back after transplant
Disease control Recruiting nowThis study tests whether the drug letermovir can prevent cytomegalovirus (CMV) from coming back in kidney or kidney/pancreas transplant patients who are at high risk. About 90 adults will take letermovir daily for 84 days and be followed for 6 months. The goal is to see if it red…
Phase: PHASE3 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Balloon stent after uterine surgery may reduce scarring
Disease control Recruiting nowThis study tests whether placing a small balloon in the uterus for 7-10 days after septum removal surgery can prevent internal scar tissue (adhesions). 320 women will be randomly assigned to receive the balloon plus hormones or hormones alone. The main goal is to see if the ballo…
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a daily pill after endometriosis surgery keep pain away?
Disease control Recruiting nowThis phase 3 trial tests whether taking Relugolix combination therapy (Rel-CT) right after endometriosis surgery leads to better quality of life and less chance of the disease coming back. About 110 women having laparoscopic or robotic surgery for endometriosis will be randomly a…
Phase: PHASE3 • Sponsor: Main Line Health • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug CT-95 targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…
Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Dual immunotherapy plus chemo may shrink cervical tumors before surgery
Disease control Recruiting nowThis phase 2 trial is testing a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery in 103 women with locally advanced cervical cancer. The goal is to see if this approach can shrink tumors enough to allow less extensive…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Smart immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Supercharged immune cells take on HPV cancers
Disease control Recruiting nowThis study tests a new immunotherapy for people with advanced HPV-related cancers, such as cervical, throat, anal, and penile cancers. Participants receive specially engineered immune cells designed to attack cancer cells carrying the HPV16 virus. The goal is to see if this treat…
Phase: PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New smart drug targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New cancer drug EXS74539 enters first human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New radioactive drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug that delivers radiation directly to cancer cells carrying a specific protein called GRPR. The study includes 48 adults with advanced cancers like prostate, breast, lung, or colon cancer that have not responded to standard treatments. The ma…
Phase: PHASE1 • Sponsor: Orano Med Theranostics, SAS • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug INV-8989 targets Hard-to-Treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug targets Hard-to-Treat cancers in people with BRCA2 or PALB2 mutations
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called CX-5461 (Pidnarulex) in people with advanced solid tumors (pancreatic, prostate, breast, or ovarian) that have specific BRCA2 or PALB2 gene mutations. The main goal is to find a safe and tolerable dose for future studi…
Phase: PHASE1 • Sponsor: Senhwa Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could less be more? new trial tailors endometrial cancer treatment to tumor type
Disease control Recruiting nowThis phase II study is testing whether women with certain types of early-stage endometrial cancer can safely receive less aggressive treatment after surgery. The approach is guided by the tumor's molecular profile—either POLE-mutated or p53 wildtype/NSMP. Around 393 participants …
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could popular Weight-Loss drugs help treat endometrial cancer?
Disease control Recruiting nowThis pilot study is testing whether combining a GLP-1 weight-loss drug (like semaglutide or tirzepatide) with a hormonal IUD can help obese patients with early-stage endometrial cancer avoid surgery or preserve fertility. Twenty participants will receive the drug and IUD, and res…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New antibody drug targets HER2 cancers in broad trial
Disease control Recruiting nowThis phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…
Phase: PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Triple threat: new combo therapy targets advanced endometrial cancer
Disease control Recruiting nowThis early-stage trial is testing whether combining chemotherapy and radiation, followed by more chemotherapy plus the immunotherapy drug dostarlimab, is safe and tolerable for people with stage IIIC node-positive endometrial cancer. The study aims to see if this approach can hel…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cancer drug enzelkitug enters first human trials
Disease control Recruiting nowThis early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New targeted cancer drug STX-478 enters human trials
Disease control Recruiting nowThis study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New antibody drug aims to shrink advanced tumors in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called JNJ-89862175 in people with advanced solid tumors (lung, kidney, ovarian, or uterine cancers that have spread). The drug is designed to deliver a toxic payload directly to cancer cells. The main goals are to find a safe dos…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial tests a combination of two drugs—DS-8201a and olaparib—in people with advanced HER2-expressing cancers that have spread or cannot be removed. DS-8201a delivers chemotherapy directly to HER2-positive tumor cells, while olaparib blocks DNA repair in cancer ce…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called MORAb-202 that targets a protein (folate receptor alpha) found on some cancer cells. It is for people with ovarian, endometrial, non-small cell lung, or triple-negative breast cancer. The trial has two parts: first to find the safest dose, then …
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New radioactive drug targets FAP-Positive tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo aims to keep ovarian cancer at bay
Disease control Recruiting nowThis study is testing whether a combination of two drugs, mirvetuximab soravtansine and olaparib, can help keep ovarian, peritoneal, or fallopian tube cancer from coming back after initial treatment. About 53 women with cancer that responded to platinum-based chemotherapy will re…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Smart radiation seeks out cancer cells in 8 tumor types
Disease control Recruiting nowThis study tests a new drug that delivers a tiny dose of radiation directly to cancer cells that have a specific marker called FAP. The trial involves 112 adults with advanced cancers of the pancreas, stomach, esophagus, colon, ovary, head/neck, sarcoma, or mesothelioma. First, a…
Phase: PHASE1, PHASE2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can weight management plus hormones reverse precancerous uterine changes and preserve fertility?
Disease control Recruiting nowThis study is for overweight or obese women aged 18–45 with atypical endometrial hyperplasia, a precancerous condition of the uterine lining. Participants will receive either a levonorgestrel-releasing IUD (Mirena) or megestrol acetate pills, combined with a weight management pro…
Phase: PHASE2, PHASE3 • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo enters human testing
Disease control Recruiting nowThis early-phase study tests whether combining two drugs, Cirtuvivint and Olaparib, is safe for women with ovarian cancer that no longer responds to platinum chemotherapy. About 50 participants will take the medications on different schedules and visit the clinic regularly for ch…
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Last-Resort cancer drug made available for patients with specific gene mutations
Disease control AVAILABLEThis program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …
Sponsor: xCures • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hormone combo aims to save fertility in early uterine cancer
Disease control Recruiting nowThis phase 2 trial tests whether a combination of a gonadotropin-releasing hormone agonist (triptorelin) and letrozole can achieve better complete response rates than standard hormone therapy (megestrol acetate or medroxyprogesterone acetate) in women with early-stage endometrial…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Can a Two-Drug punch wake up 'Cold' tumors?
Disease control Recruiting nowThis study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo aims to save wombs in young women with uterine cancer
Disease control Recruiting nowThis study tests a combination of an immune-boosting drug (TQB2450) and a high-dose hormone (progestin) to treat young women (ages 18-45) with a specific type of early-stage endometrial cancer (MMRd). The goal is to eliminate the cancer while preserving the uterus so patients can…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cancer drug CTX-10726 enters first human tests
Disease control Recruiting nowThis early-stage trial tests an experimental drug called CTX-10726 in about 70 people with advanced gastroesophageal, liver, endometrial, or kidney cancers that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. Participants …
Phase: PHASE1 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New antibody drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and to check for side effects. About …
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail targets Virus-Linked cancers in early trial
Disease control Recruiting nowThis phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill targets HER2 cancers in promising trial
Disease control Recruiting nowThis Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Boric acid inserts aim to cure yeast infections in new trial
Disease control Recruiting nowThis study tests whether boric acid vaginal inserts (600 mg) taken for 7 or 14 days can safely and effectively treat yeast infections. About 400 women aged 12 and older with active symptoms will participate. The goal is to see if all signs and symptoms disappear without needing m…
Phase: PHASE3 • Sponsor: pH-D Feminine Health LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for recurrent endometrial cancer: Rina-S faces off against standard chemo
Disease control Recruiting nowThis study compares a new drug called Rina-S to standard chemotherapy (paclitaxel or doxorubicin) in people with endometrial cancer that has returned or worsened after platinum-based chemo and immunotherapy. About 660 participants will be randomly assigned to receive either Rina-…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for womb cancer: drug duo aims to slow tumor growth
Disease control Recruiting nowThis study tests whether adding sacituzumab tirumotecan (Sac-TMT) to pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without the cancer getting worse. About 1,100 participants with a specific type of endometrial cancer (pMMR) will receive eith…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a common antibiotic slash deaths from brain TB?
Disease control Recruiting nowThis phase 2 trial tests whether adding the antibiotic doxycycline to standard treatment can reduce deaths and severe brain damage in adults with tuberculosis of the brain or its lining. About 200 participants will receive either doxycycline or a placebo for 8 weeks, alongside us…
Phase: PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo aims to extend remission in ovarian cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New Antibody-Drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo aims to wipe out hidden ovarian cancer cells
Disease control Recruiting nowThis study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better eliminate remaining cancer in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assi…
Phase: PHASE1, PHASE2 • Sponsor: Imunon • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Herbal hope for ovarian health: new trial tests ancient remedy
Disease control Recruiting nowThis study tests whether a traditional Chinese herbal formula (Bu Shen Yi Qi) combined with the hormone DHEA can improve ovarian function in women with diminished ovarian reserve. 74 women aged 20-40 will receive either the herbal formula plus DHEA or a placebo plus DHEA for 12 w…
Phase: PHASE1, PHASE2 • Sponsor: Jiangxi University of Traditional Chinese Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New smart chemo targets tumors, spares healthy tissue
Disease control Recruiting nowThis early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…
Phase: PHASE1 • Sponsor: Avacta Life Sciences Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo trial offers hope for ovarian cancer patients
Disease control Recruiting nowThis study tests an experimental drug called IMGN151, alone or with other cancer treatments, in about 377 adults with gynecologic cancers like ovarian cancer. The goal is to check safety and find the best dose. Participants get the drug through an IV and will have regular check-u…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for rare, deadly gynecologic cancers: drug combo trial launches
Disease control Recruiting nowThis clinical trial is testing whether a combination of two drugs—dostarlimab (an immunotherapy) and niraparib (a PARP inhibitor)—works better than standard chemotherapy for women with a rare and aggressive type of uterine or ovarian cancer called carcinosarcoma. The study will e…
Phase: PHASE2, PHASE3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for hard-to-treat ovarian cancer: experimental drug targets key protein
Disease control Recruiting nowThis study tests a new drug called INCB123667 in 160 people with a type of ovarian cancer that no longer responds to platinum chemotherapy and has high levels of a protein called cyclin E1. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a longer clomid regimen boost IVF success for women with low egg supply?
Disease control Recruiting nowThis study compares a longer course of the fertility drug Clomid against the standard short course for women with diminished ovarian reserve undergoing IVF. The goal is to see if the extended protocol leads to more mature eggs retrieved while reducing the number of injections and…
Phase: PHASE4 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New gene therapy combo aims to boost ovarian cancer survival
Disease control Recruiting nowThis phase 3 trial tests whether adding a gene therapy called IMNN-001 (given into the abdomen) to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer. About 500 newly diagnosed patients will be randomly assigned to receive e…
Phase: PHASE3 • Sponsor: Imunon • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New stitch could speed up hysterectomy surgery
Disease control Recruiting nowThis study compares a new barbed suture (SYMMCORA) with a standard one (V-Loc) for closing the vaginal cuff after laparoscopic hysterectomy. The goal is to see if the new suture reduces stitching time without increasing complications. About 132 women having elective laparoscopic …
Sponsor: Aesculap AG • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a 6-Month drug cocktail beat 9 months for brain TB?
Disease control Recruiting nowThis study compares a 6-month treatment using high doses of four antibiotics against the standard 9-month therapy for tuberculous meningitis, a serious brain infection. About 330 adults and teens without HIV will take part. The goal is to see if the shorter regimen is as safe and…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug IACS-6274 enters early human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…
Phase: PHASE1 • Sponsor: SEED Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug Rina-S shows promise in battling Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug lorigerlimab takes on Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis phase 2 trial is testing a drug called lorigerlimab in about 80 people with advanced ovarian or clear cell gynecologic cancers that have stopped responding to platinum chemotherapy. Lorigerlimab is a bispecific antibody designed to activate the immune system against tumors. …
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Ovarian cancer surgery showdown: tumor removal vs. bowel resection
Disease control Recruiting nowThis study looks at two different surgeries for advanced ovarian cancer that has spread to the bowel. One method removes only the tumor from the bowel, while the other removes a piece of the bowel along with the tumor. The goal is to see which approach helps patients live longer …
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cocktail aims to boost immune attack on ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New immunotherapy combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis phase 2 trial is testing two immunotherapy drugs, durvalumab and tremelimumab, alone or together, in 60 people with colorectal or endometrial cancer. The goal is to see if these drugs can shrink tumors or slow cancer growth. The study focuses on patients with different genet…
Phase: PHASE2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two cancer markers at once. It is for people with ovarian, peritoneal, or fallopian tube cancer that has come back or not responded to standard treatments. The therapy is personalize…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Recruiting nowThis study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug INV-6452 targets Hard-to-Treat breast cancers
Disease control Recruiting nowThis study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug hope for patients with advanced cancers
Disease control Recruiting nowThis study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cell therapy targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system atta…
Phase: PHASE1 • Sponsor: Zelluna Immunotherapy AS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New particles aim to shrink fibroids without surgery
Disease control Recruiting nowThis study is testing Bearing nsPVA particles, used during a procedure called uterine artery embolization, to treat uterine fibroids in 100 women. The goal is to see if these particles safely block blood flow to fibroids, reducing symptoms like pain and heavy bleeding. Participan…
Sponsor: Merit Medical Systems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Natural prebiotic could beat antibiotics for thrush and BV
Disease control Recruiting nowThis study tests whether lactoferrin, a natural prebiotic from cow's milk, can be a good alternative to antibiotic tablets for women with bacterial vaginosis (BV) or thrush. Researchers will recruit 114 women and give half lactoferrin vaginal pessaries for 3 weeks, while the othe…
Phase: NA • Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug ERX-315 enters first human tests for tough cancers
Disease control Recruiting nowThis early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing do…
Phase: PHASE1 • Sponsor: EtiraRx Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug FOG-001 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for recurrent ovarian cancer? early trial combines novel PARP inhibitor with chemo
Disease control Recruiting nowThis early-stage study tests a new experimental drug (NMS-03305293) combined with a standard chemotherapy (topotecan) in about 24 people whose ovarian cancer has returned after previous treatments. The main goals are to check safety and find the best dose, while also seeing if th…
Phase: PHASE1 • Sponsor: Nerviano Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New stent aims to prevent uterine scarring in women
Disease control Recruiting nowThis study tests a new uterine stent to prevent intrauterine adhesions (scar tissue) after surgery in women aged 20-40. 200 participants will be randomly assigned to receive either the new stent or standard care (uterine ring, balloon, and gel). The goal is to see if the stent re…
Phase: NA • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Uterine septum surgery may boost IVF success in infertile women
Disease control Recruiting nowThis study looks at whether a surgery called transcervical resection of the septum (TCRS) can improve pregnancy outcomes for infertile women with a uterine septum who are planning IVF. The trial will compare live birth rates between women who get the surgery and those who don't. …
Phase: NA • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for advanced cancer: first human trial of GS-0201 begins
Disease control Recruiting nowThis early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for endometrial cancer: targeted drug trial launches
Disease control Recruiting nowThis phase 3 trial tests whether the targeted drug trastuzumab deruxtecan (T-DXd) works better than standard chemotherapy after surgery for HER2-positive endometrial cancer. About 710 adults with early-stage or locally advanced disease will be randomly assigned to receive T-DXd o…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Precision genetic therapy aims to slow rare brain disease
Disease control Recruiting nowThis early-stage trial tests a drug called atipeksen for people with Ataxia-Telangiectasia (A-T), a rare genetic disease that affects movement and coordination. The drug is designed to fix a specific genetic error in the ATM gene and is given via spinal injection. The study will …
Phase: PHASE1, PHASE2 • Sponsor: Timothy Yu • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New cancer drug HLX316 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…
Phase: PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug duo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.
Phase: PHASE1, PHASE2 • Sponsor: Biocity Biopharmaceutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy offers hope for advanced cervical cancer patients
Disease control Recruiting nowThis study tests a combination of immunotherapy drugs (PD-1/PD-L1 inhibitors) with chemotherapy, with or without bevacizumab, in 120 adults with metastatic, persistent, or recurrent cervical cancer. The goal is to see if this approach helps patients live longer and controls the d…
Phase: PHASE2, PHASE3 • Sponsor: N.N. Alexandrov National Cancer Centre • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug aimed at Hard-to-Treat ovarian cancer shows promise in trial
Disease control Recruiting nowThis study tests a drug called mirvetuximab soravtansine (MIRV) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy and has high levels of a protein called FRα. The drug delivers a cancer-killing agent directly to tumor ce…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New immunotherapy combo shows promise for tough cancers
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Uterine infection linked to infertility: antibiotics may boost pregnancy chances
Disease control Recruiting nowThis study looks at 100 women with infertility to see how common chronic endometritis (a long-term inflammation of the womb lining) is and whether antibiotic treatment can improve their chances of getting pregnant and having a healthy baby. Participants will have a camera test an…
Sponsor: Faculty Hospital Kralovske Vinohrady • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Lymph node surgery may boost cervical cancer treatment
Disease control Recruiting nowThis study looks at whether surgically removing para-aortic lymph nodes before standard chemoradiation can improve disease-free survival in people with stage IIIC1 cervical cancer. About 510 participants will be randomly assigned to either standard treatment or surgery plus tailo…
Phase: PHASE3 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New smart drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new antibody called HMBD-001 combined with two existing cancer drugs (cetuximab and docetaxel) in people with advanced squamous cell cancers of the lung, head and neck, esophagus, cervix, or skin. The goal is to see if the combination is safe and can shrink tum…
Phase: PHASE1, PHASE2 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug DSB2455 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…
Phase: PHASE1 • Sponsor: Duke Street Bio Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for tough ovarian cancer: first human trial of MEN2501 launches
Disease control Recruiting nowThis early-stage trial tests a new drug called MEN2501 in about 100 adults with ovarian cancer that has stopped responding to platinum chemotherapy. The main goals are to check safety and find the best dose. Researchers will also watch for signs that the drug shrinks tumors or sl…
Phase: PHASE1 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…
Phase: PHASE1, PHASE2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Aerosol chemo spray shows promise for Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study is for women with advanced ovarian, fallopian tube, or peritoneal cancer whose tumors did not shrink enough with standard chemotherapy. Researchers are testing a new method called PIPAC, which delivers chemotherapy as a pressurized spray directly into the abdomen, comb…
Phase: PHASE1 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New radioactive 'Smart Bomb' targets Hard-to-Treat lung cancer
Disease control Recruiting nowThis study tests a new drug that delivers radiation directly to cancer cells carrying a protein called DLL3, found in small cell lung cancer and other solid tumors. The trial enrolls 138 adults whose cancer has progressed after at least two prior treatments. The goal is to check …
Phase: PHASE1, PHASE2 • Sponsor: Molecular Partners AG • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of cell therapy called p95HER2.CAR-TECH2Me for people with advanced HER2-positive breast, gastric, or endometrial cancers that have spread. The treatment uses a patient's own immune cells, which are modified in a lab to better recogniz…
Phase: PHASE1 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for advanced cancer: combo therapy trial launches
Disease control Recruiting nowThis study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …
Phase: PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo aims to outsmart resistant ovarian cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two targeted drugs—abemaciclib and olaparib—can help women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll 42 participants to find the safest dose and check for side effects.…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a pill that blocks estrogen help fight rare uterine cancers?
Disease control Recruiting nowThis phase 2 trial is testing elacestrant, a pill that breaks down estrogen receptors, in 30 people with advanced uterine sarcomas that are fueled by estrogen. The goal is to see if the drug can shrink tumors or slow their growth. Participants must have tumors that strongly expre…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for ovarian cancer: targeted drug R-DXd enters key trial
Disease control Recruiting nowThis study tests a new drug called raludotatug deruxtecan (R-DXd) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy. The drug is designed to target and kill cancer cells while sparing healthy ones. About 860 participants…
Phase: PHASE2, PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug BGB-B455 targets tough tumors in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called BGB-B455 in about 90 people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find a safe dose and see what side effects occur. The study has two parts: first finding the right dose,…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests an experimental oral drug, JAB-30355, in adults with advanced solid tumors that have a specific change in the TP53 gene (called Y220C). The trial aims to find a safe dose and see if the drug can shrink tumors. About 144 participants who have already tried at leas…
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for hard-to-treat cancers: combo drug trial launches
Disease control Recruiting nowThis study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Glowing dye could cut bowel leak risk in ovarian cancer surgery
Disease control Recruiting nowThis study tests whether using a fluorescent dye and special camera during ovarian cancer surgery can help surgeons see blood flow in the bowel and reduce the risk of leaks after reconnecting it. About 310 women with ovarian cancer who need bowel surgery will be randomly assigned…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo tested for ovarian cancer: will it work?
Disease control Recruiting nowThis early-phase trial is testing how the antifungal drug itraconazole affects the levels of a new cancer drug, AZD5335, in the body. The study involves 24 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Newer surgery may offer safer fix for pelvic prolapse
Disease control Recruiting nowThis study compares two laparoscopic surgeries for apical prolapse, a common condition in aging women. The standard surgery, sacrocolpopexy, is effective but technically challenging. The newer pectopexy may be safer and faster to learn. Thirty women with advanced prolapse will be…
Phase: NA • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New CAR t cell therapy takes on Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-phase trial is testing a new treatment for ovarian cancer that has returned after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is to find a safe dose and see what side…
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Supercharged immune cells take on hard-to-treat cancers
Disease control Recruiting nowThis study tests a new treatment called KSQ-004EX for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells (tumor infiltrating lymphocytes) that are genetically modified to be more powerful against cancer…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
HIV drug shows promise against Hard-to-Treat vulvar cancer
Disease control Recruiting nowThis early-stage study tests whether adding the HIV drug nelfinavir to standard chemotherapy (cisplatin) and radiation can safely treat advanced vulvar cancer that has spread and cannot be surgically removed. About 25 adults with stage II-IVA vulvar cancer will take part. The mai…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental combo therapy targets multiple cancers in new trial
Disease control Recruiting nowThis study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…
Phase: PHASE1, PHASE2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New mRNA drug takes on HER2 cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new mRNA-based drug called MT-304, alone or with the immunotherapy nivolumab, in adults with advanced HER2-expressing solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether it shrinks tumors. Abou…
Phase: PHASE1 • Sponsor: Myeloid Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Radioactive 'Bullets' aim to stop ovarian cancer spread in new trial
Disease control Recruiting nowThis study tests a single injection of Radspherin®, a radioactive treatment given directly into the abdomen, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has spread to the lining of the belly. About 114 participants will receive either stand…
Phase: PHASE2 • Sponsor: Oncoinvent Solutions AS • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug duo aims to outperform chemo in rare ovarian cancer
Disease control Recruiting nowThis phase 3 trial tests whether a new immunotherapy drug (QL1706) combined with bevacizumab can slow cancer growth better than standard chemotherapy in women with advanced ovarian clear cell carcinoma. About 226 participants will be randomly assigned to receive either the experi…
Phase: PHASE3 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New cocktail aims to stamp out stubborn ovarian cancer cells
Disease control Recruiting nowThis study tests whether a combination of three drugs—pembrolizumab, bevacizumab, and low-dose cyclophosphamide—can help control high-grade ovarian cancer that remains after standard frontline therapy. About 20 women with minimal residual disease will receive the treatment to see…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo shows promise for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis study tests two drugs, pembrolizumab and lenvatinib, in people with a type of uterine cancer that has come back after initial treatment. The cancer must be mismatch repair proficient, meaning it has a specific genetic feature. The goal is to see if this drug combination can …
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a new drug called LBL-024 combined with the chemotherapy paclitaxel in people with ovarian cancer that has become resistant to platinum-based treatments. The trial involves 110 participants and aims to see if the combination can shrink tumors and delay disease pr…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a simple urine test replace the pap smear for cervical cancer screening?
Diagnosis Recruiting nowThis study investigates whether urine samples can be used to screen for cervical cancer in women living with HIV. Researchers will compare the accuracy of urine HPV testing with self-collected and provider-collected samples to detect cervical precancer (CIN2 or worse). The goal i…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
AI-Powered blood test could spot five cancers before symptoms show
Diagnosis Recruiting nowThis study is testing a new blood test called EXoPred that uses artificial intelligence and laser technology to find tiny particles from cancer cells. The goal is to detect breast, colon, pancreatic, ovarian, and lung cancers at an early stage. Researchers will enroll 1,400 peopl…
Sponsor: EXoPERT • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
AI ultrasound could bring lifesaving pregnancy checks to remote villages
Diagnosis Recruiting nowThis study tests whether a smartphone-based AI ultrasound, operated by health workers with minimal training, can accurately estimate gestational age, detect placenta position, and identify fetal presentation in pregnant women in rural Democratic Republic of the Congo. The goal is…
Sponsor: SOIK Corporation Sarl • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New blood test could spot 10 cancers before symptoms start
Diagnosis Recruiting nowThis study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New PET tracer could sharpen cancer detection
Diagnosis Recruiting nowThis study tests a new radioactive tracer called [18F]FPyQCP for PET scans to see if it can better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the tracer and have a PET/CT scan. The goal i…
Phase: PHASE1, PHASE2 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
New scan could spot hidden cancers in the belly
Diagnosis Recruiting nowThis study tests a new PET/CT scan using a radioactive tracer called GEH300079 to detect peritoneal carcinomatosis—cancer that has spread to the lining of the abdomen—in people with colorectal, stomach, ovarian, or pancreatic cancer. About 175 adults with known or suspected sprea…
Phase: PHASE2, PHASE3 • Sponsor: GE Healthcare • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New test could spare women unnecessary biopsies for uterine cancer
Diagnosis Recruiting nowThis study is working on a new, non-invasive test to help rule out uterine cancer in women aged 45 and older who have abnormal bleeding. Researchers will collect samples from 4,500 women to see how well the test detects cancer and identifies benign cases. If successful, it could …
Sponsor: PinkDx, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple Self-Swap replace the speculum for cervical cancer screening?
Diagnosis Recruiting nowThis study is testing whether self-collected vaginal samples for HPV testing work as well as samples collected by a doctor during a pelvic exam. The goal is to make cervical cancer screening more accessible and comfortable. About 500 people referred for colposcopy or cervical pro…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New MRI technique could spot dangerous placenta adhesions before delivery
Diagnosis Recruiting nowThis trial investigates whether advanced MRI scans can better detect placenta adhesion abnormalities (PAA) in pregnant women between 30 and 38 weeks. PAA occurs when the placenta grows too deeply into the uterine wall, raising risks of severe bleeding and emergency hysterectomy d…
Phase: NA • Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Could a menstrual cup replace painful biopsies for cancer screening?
Diagnosis Recruiting nowThis study looks at whether a menstrual cup can collect enough uterine tissue to screen for endometrial cancer, especially in women with Lynch syndrome who are at higher risk. About 25 participants will use a menstrual cup at home and also have a standard biopsy, then compare the…
Phase: NA • Sponsor: Jessica D. St. Laurent, MD • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
AI reads ultrasound to spot hidden uterine cancer
Diagnosis Recruiting nowThis study explores whether an artificial intelligence (AI) program can accurately identify endometrial cancer or precancerous changes by analyzing standard transvaginal ultrasound images. Researchers will compare the AI's predictions with results from endometrial biopsies in 300…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
AI reads ultrasound videos to spot dangerous placenta condition
Diagnosis Recruiting nowThis study is testing a new artificial intelligence (AI) system that reads ultrasound videos to help doctors diagnose placenta accreta spectrum (PAS), a condition where the placenta grows too deeply into the womb. About 561 pregnant women aged 18-45 with certain risk factors will…
Sponsor: FANG HE • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
AI blood test could spot endometriosis without surgery
Diagnosis Recruiting nowThis study tests a new blood test called EndoCheck that uses artificial intelligence to detect endometriosis in women with chronic pelvic pain. Researchers aim to see if the test is accurate enough to replace or reduce the need for exploratory surgery. About 1,200 women aged 14 t…
Sponsor: Aspira Women's Health • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
Glow-in-the-Dark dye helps surgeons spot hidden cancer
Diagnosis Recruiting nowThis study tests a dye called CYTALUX (pafolacianine) that attaches to cancer cells and glows under a special camera during surgery. About 50 adults with certain cancers (like esophageal, pancreatic, or gynecologic) will get the dye before surgery. The goal is to see if the glowi…
Phase: PHASE2 • Sponsor: John Waters • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
Vaginal fluid may hold key to early cancer detection
Diagnosis Recruiting nowThis study looks at whether vaginal fluid can help detect gynaecological cancers early. Researchers will collect samples from 250 women, including those with and without cancer, to compare specific markers. The goal is to develop a non-invasive test that could improve detection a…
Sponsor: University Hospital Southampton NHS Foundation Trust • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
AI-Powered urine test could revolutionize cervical cancer screening in Low-Income countries
Diagnosis Recruiting nowThis study is testing a new, affordable AI system to screen for cervical cancer in low- and middle-income countries. The AI analyzes urine samples and cervical images to detect high-risk HPV and precancerous changes. About 3,200 unscreened women aged 25-49 in Zimbabwe will take p…
Phase: NA • Sponsor: International Agency for Research on Cancer • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New imaging agent could spot multiple cancers with one scan
Diagnosis Recruiting nowThis study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…
Phase: PHASE2, PHASE3 • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Radioactive tracer could spot hidden cancers in ovarian, lung, and pancreatic tumors
Diagnosis Recruiting nowThis study tests a new radioactive imaging agent that targets a protein called MSLN, found on some cancer cells. Researchers will use PET scans to see if this agent can better detect and stage ovarian cancer, lung adenocarcinoma, and pancreatic cancer in 100 patients and healthy …
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Jun 27, 2026 12:39 UTC
-
New Low-Cost HPV test could save lives in poor countries
Diagnosis Recruiting nowThis study tests a low-cost HPV test that can be done in one visit, so women get results and treatment on the same day. It aims to reduce the number of women lost to follow-up in cervical cancer screening programs. The study will enroll 1,000 women in remote areas of El Salvador.
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:38 UTC
-
Bringing cervical cancer screening to women with HIV: can Home-Delivered HPV tests make a difference?
Diagnosis Recruiting nowThis study compares two ways to offer cervical cancer screening to women living with HIV: standard clinic-based screening versus adding community outreach where health workers provide HPV self-collection kits at home or in community settings. About 7,600 women across multiple cli…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:38 UTC
-
Could a Full-Body scan replace surgery for endometriosis diagnosis?
Diagnosis Recruiting nowThis study is testing whether a special full-body PET/CT scan can spot endometriosis without needing surgery. Up to 30 women with suspected endometriosis will get two scans using different tracers that highlight bleeding and scarring. The scan results will be compared with findin…
Sponsor: University of Edinburgh • Aim: Diagnosis
Last updated Jun 27, 2026 12:38 UTC
-
Saliva test for endometriosis: will it improve Women's lives?
Diagnosis Recruiting nowThis study follows 20,000 women who take a new saliva test (Endotest) to diagnose endometriosis. Researchers want to see how the test result—positive or negative—affects their quality of life, emotions, and care decisions. Participants fill out questionnaires and share medical da…
Sponsor: ZIWIG • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New blood test could spot ovarian cancer type before surgery
Diagnosis Recruiting nowThis study aims to improve how doctors tell the difference between borderline ovarian tumors and early-stage invasive ovarian cancer before surgery. Researchers will test a panel of nine blood-based biomarkers in 400 women with suspicious ovarian cysts. If successful, this could …
Sponsor: KU Leuven • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
New scan could spot hidden cancers better than current methods
Diagnosis Recruiting nowThis study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
Hawaiian superfood tested to ward off pregnancy diabetes
Prevention Recruiting nowThis pilot study is testing whether eating fermented poi every day for four weeks can improve the gut health of pregnant women and lower their risk of developing gestational diabetes. Fifty pregnant women between 10 and 24 weeks will eat one pound of poi daily and receive nutriti…
Phase: NA • Sponsor: University of Hawaii • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New program aims to boost cervical cancer screening in high-risk women
Prevention Recruiting nowThis study tests a program called PINPOINT that helps women with obesity or diabetes get screened for cervical cancer. About 20 women who are behind on screening will be offered options like self-collection or a Pap smear. The goal is to see if the program is practical and well-l…
Phase: NA • Sponsor: University of Florida • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
New program aims to cut cervical cancer risk in vulnerable women
Prevention Recruiting nowThis study tests a program called SAKHI HPV for women in India who have both HPV and HIV. The program provides support from community health workers, group sessions, and nutrition education to help women stay healthy and reduce their risk of cervical cancer. Researchers will comp…
Phase: NA • Sponsor: University of California, Irvine • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
Could removing fallopian tubes first prevent ovarian cancer without early menopause?
Prevention Recruiting nowThis study looks at whether removing the fallopian tubes first and delaying ovary removal is as safe as removing both at once to prevent ovarian cancer in women with BRCA or other high-risk gene mutations. About 100 premenopausal women will choose either the new two-step approach…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
No-needle acupressure and gentle exercise may stop period cramps before they start
Prevention Recruiting nowThis study tests two self-care methods—virtual ear acupressure and Baduanjin qigong—to prevent or reduce period pain in 145 women aged 16–35 with primary dysmenorrhea. Participants will be randomly assigned to one of three groups and practice their assigned technique for 12 weeks…
Phase: PHASE2, PHASE3 • Sponsor: Nanyang Technological University • Aim: Prevention
Last updated Jun 27, 2026 14:03 UTC
-
Simple video may boost ovarian cancer prevention during other surgeries
Prevention Recruiting nowThis study tests whether an educational video can increase women's interest in having their fallopian tubes removed during non-gynecologic surgery to prevent ovarian cancer. Participants watch a video and complete questionnaires before and after. The study involves 266 women aged…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Green tea and vitamin D3 may stop fibroids returning after surgery
Prevention Recruiting nowThis study tests whether taking green tea extract (EGCG) and vitamin D3 daily can prevent uterine fibroids from growing back after surgical removal. About 240 women who have had fibroid surgery will receive either the supplements or a placebo. The goal is to see if this simple co…
Phase: PHASE2 • Sponsor: Sheikh Shakhbout Medical City • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Could a daily aspirin save mothers and babies from hypertension risks?
Prevention Recruiting nowThis study tests whether taking 150 mg of aspirin daily, starting before 20 weeks of pregnancy, can prevent serious problems like preeclampsia, poor fetal growth, placental abruption, preterm birth, and death in pregnant women with chronic high blood pressure. About 500 women wil…
Phase: PHASE3 • Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
At-Home HPV tests could boost cervical cancer screening in border communities
Prevention Recruiting nowThis study tests whether at-home HPV self-sampling (using urine or a vaginal swab) can help more people get screened for cervical cancer compared to the traditional in-clinic Pap smear. About 735 Latinx individuals aged 30-65 who haven't had a Pap test in at least three years wil…
Phase: NA • Sponsor: University of Texas at Austin • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
HPV vaccine and screening brought to women who need it most
Prevention Recruiting nowThis study aims to make cervical cancer prevention easier for women who often miss out on routine care, such as those experiencing homelessness, substance use, or incarceration. Researchers will offer the HPV vaccine (Gardasil-9) and a self-swab test during regular sexual health …
Sponsor: University of Edinburgh • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Home workouts via video calls could ease cancer side effects
Symptom relief Recruiting nowThis study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Home-Based yoga and brain training may ease teen period pain
Symptom relief Recruiting nowThis study tests whether telerehabilitation-based cognitive exercise therapy and yoga can reduce pain, improve physical function, and boost quality of life in adolescent girls with primary dysmenorrhea (painful periods). Forty-two teens aged 10–19 will participate in 12 weeks of …
Phase: NA • Sponsor: Acibadem University • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Can Mind-Body techniques and drugs ease stress during ovarian cancer surgery?
Symptom relief Recruiting nowThis pilot study tests whether a combination of stress-reducing drugs (propranolol and etodolac) and mind-body techniques (resilience training and music therapy) can help women with advanced ovarian cancer feel less stress before, during, and after surgery. The study will enroll …
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Wearable Brain-Zapping device aims to ease Period-Related mood and brain fog
Symptom relief Recruiting nowThis study tests a 12-week digital program called Samphire Guided Care for people with menstrual or pelvic health conditions like PMS, endometriosis, or menopause. The program combines a wearable device that gently stimulates the brain, coaching, and symptom tracking to see if it…
Sponsor: Samphire Group, Inc. • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Could a simple alcohol injection ease endometrioma pain?
Symptom relief Recruiting nowThis study tests whether ultrasound-guided alcohol sclerotherapy can reduce pelvic pain and improve quality of life in women aged 18-45 with ovarian endometriomas. Participants are randomly assigned to receive the procedure or no treatment (expectant management) and are followed …
Phase: NA • Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Can massage or music ease period pain? new trial investigates
Symptom relief Recruiting nowThis study tests whether connective tissue massage or music-based relaxation can reduce pain and other symptoms in women with primary dysmenorrhea (painful periods). Thirty-six women will be randomly assigned to massage, relaxation, or a control group. The treatments are given be…
Phase: NA • Sponsor: Pamukkale University • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Could fasting boost chemo outcomes? small trial tests the idea in ovarian cancer
Symptom relief Recruiting nowThis study looks at whether intermittent fasting (not eating for 16 hours a day, 5 days a week) is safe and doable for people with advanced ovarian cancer who are getting chemotherapy before surgery. Twenty participants will either follow the fasting schedule or standard diet adv…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Could sound waves soothe a painful condition? new study tests shock therapy for vulvodynia
Symptom relief Recruiting nowThis study looks at whether low-intensity shock wave therapy can help women with vulvodynia, a chronic pain condition of the vulva. Researchers will review medical records from 50 women who already received four sessions of this non-invasive treatment in routine care. They want t…
Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Can a Culturally-Tailored therapy reduce anxiety in advanced cancer patients?
Symptom relief Recruiting nowThis study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
VR glasses may soothe anxiety in High-Risk pregnancies
Symptom relief Recruiting nowThis study tests whether watching nature-themed videos through virtual reality glasses can reduce anxiety and distress in pregnant women hospitalized with premature rupture of membranes. 176 women will either receive standard care or watch calming nature videos twice a day for th…
Phase: NA • Sponsor: Selcuk University • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New telehealth program aims to ease the burden of advanced cancer for patients and families
Symptom relief Recruiting nowThis study tests a program called BOLSTER, which offers six telehealth sessions with a nurse to help patients with advanced gynecologic or gastrointestinal cancers and their care partners build skills, manage symptoms, and cope with challenges. Participants also get access to a w…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to stop cancer wasting
Symptom relief Recruiting nowThis Phase 2 trial tests a drug called ASCA101 in 135 adults with solid tumors (colorectal, ovarian, or lung cancer) who have cachexia—a condition causing severe weight loss and muscle wasting. Participants receive either ASCA101, an active control (Megace), or a placebo for 12 w…
Phase: PHASE2 • Sponsor: MetaFines • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New tool aims to improve talks between ovarian cancer patients and doctors
Symptom relief Recruiting nowThis study tests a tool called CASI that helps ovarian cancer patients, their caregivers, and doctors set a shared plan for each visit. The goal is to see if using this tool is practical and helpful. About 112 people with advanced ovarian cancer and their caregivers will take par…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can gentle movement beat core workouts for PMS relief?
Symptom relief Recruiting nowThis study tests whether somatic movement therapy or core strengthening exercises better reduce PMS symptoms, stress, and improve quality of life. Thirty-six women aged 18-35 with PMS will do one of the two programs for six weeks. Researchers will measure changes using standard q…
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New exercise combo may offer relief for uterine prolapse sufferers
Symptom relief Recruiting nowThis study looks at whether combining two types of pelvic floor exercises—functional movement retraining and hypopressive exercises—can reduce pain, improve bladder and bowel symptoms, and boost quality of life in women with mild uterine prolapse. Thirty-two women aged 30-60 with…
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Fish oil and band workouts: a new hope against cancer muscle loss?
Symptom relief Recruiting nowThis study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…
Phase: NA • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New shot aims to reverse cancer wasting
Symptom relief Recruiting nowThis early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…
Phase: PHASE1 • Sponsor: Kexing Biopharm Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New proton therapy aims to reduce bowel side effects in gynecologic cancer patients
Symptom relief Recruiting nowThis study is testing a precise type of radiation (proton beam) given to the pelvis after surgery for cervical, uterine, or endometrial cancer. The goal is to see if it causes fewer bowel side effects than standard radiation. About 25 adults who need pelvic radiation after surger…
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Can a breast cancer drug shrink fibroids? new trial aims to find out
Symptom relief Recruiting nowThis study tests whether the drug letrozole can improve symptoms and shrink fibroids in women with uterine fibroids. 140 participants will receive either letrozole or a placebo daily for 12 weeks. The main goal is to see if letrozole reduces symptom severity and improves quality …
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Can eye drops save sight during ovarian cancer treatment?
Symptom relief Recruiting nowThis phase 2 trial tests whether different eye drops can prevent or reduce eye problems caused by the cancer drug mirvetuximab soravtansine in 100 people with recurrent ovarian cancer. Participants will receive the cancer drug along with either lubricating drops, steroid drops, o…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New writing therapy aims to ease fear in advanced cancer patients
Symptom relief Recruiting nowThis study tests a new program called EASE, which uses a simple writing exercise to help adults with advanced cancer manage their fear of the future and related trauma symptoms. The study will include 250 people with advanced solid tumors, glioblastoma, or certain ovarian or lung…
Phase: NA • Sponsor: University of Colorado, Boulder • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Could a common mental health drug prevent weight loss in cancer patients?
Symptom relief Recruiting nowThis study is testing whether a low dose of olanzapine, a drug usually used for mental health conditions, can prevent or treat the loss of appetite and weight that often happens in cancer patients receiving chemotherapy. About 100 adults with stomach or ovarian cancer will take t…
Phase: PHASE3 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can simple exercises or relaxation ease painful periods? new study investigates.
Symptom relief Recruiting nowThis study looks at whether aerobic exercise or a relaxation method (Jacobson's technique) works better for reducing pain, tiredness, and improving daily life in young women with painful periods. About 58 women aged 17-24 with mild period pain will be randomly placed into one of …
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Can tylenol and advil replace opioids after tubal ligation?
Symptom relief Recruiting nowThis study compares two pain management plans after laparoscopic tubal sterilization: one with opioids and one without. About 38 women will report their pain levels and satisfaction. The goal is to see if non-opioid drugs like Tylenol and ibuprofen work just as well.
Phase: PHASE4 • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Mind over menstrual pain: brain retraining could offer Drug-Free relief
Symptom relief Recruiting nowThis trial tests whether graded motor imagery—a brain-training program that includes recognizing body positions, imagining pain-free movements, and using mirror therapy—can reduce pain sensitivity and intensity in women with primary dysmenorrhea (painful periods with no medical c…
Phase: NA • Sponsor: Dr. Mehak Naeem • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Could a blood plasma infusion help women with thin uterine lining get pregnant?
Symptom relief Recruiting nowThis study tests whether infusing platelet-rich plasma (PRP) into the uterus can thicken the uterine lining and improve pregnancy success in women with infertility who have had failed IVF cycles due to a thin lining. About 62 women will receive either PRP or a placebo during a fr…
Phase: NA • Sponsor: Reproductive Medicine Associates of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Chill out chemo nerve pain: cold wraps plus compression tested in new trial
Symptom relief Recruiting nowThis study tests whether using cold wraps plus compression (cryocompression) on hands and feet during chemotherapy can reduce nerve damage (peripheral neuropathy) in people with gynecologic cancer. About 190 participants will be randomly assigned to receive either cryocompression…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Magnetic pulses may soothe chemo nerve pain in cancer survivors
Symptom relief Recruiting nowThis study tests whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) can reduce nerve pain caused by chemotherapy in breast and gynecologic cancer survivors. About 19 women who have persistent pain after chemo will receive…
Phase: NA • Sponsor: University of Utah • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New study aims to break the silence on sex after gynecologic cancer
Symptom relief Recruiting nowThis study tests whether an educational video and workbook can help gynecologic cancer patients bring up sexual health concerns with their cancer care team. About 200 patients will either receive the video and workbook plus a resource guide, or just the guide alone. Researchers w…
Phase: NA • Sponsor: Fox Chase Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Exercise before ovarian cancer surgery may reduce frailty and boost recovery
Symptom relief Recruiting nowThis study tests whether a 4-week exercise program before surgery can reduce frailty and improve recovery in women with advanced ovarian cancer. Frailty affects about half of these patients and often leads to worse surgical outcomes and chemotherapy delays. The program includes l…
Phase: NA • Sponsor: Nova Scotia Health Authority • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Can a simple pill make fibroid surgery safer?
Symptom relief Recruiting nowThis study tests whether giving misoprostol (a drug often used for stomach ulcers and labor) before hysteroscopic fibroid removal can reduce the amount of fluid absorbed by the body during surgery. Too much fluid can be dangerous. Forty women with small fibroids (1-3 cm) will rec…
Phase: PHASE4 • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Could a simple supplement protect your gut during radiation?
Symptom relief Recruiting nowThis study tests whether taking a short chain fatty acid supplement can reduce gut-related side effects in people receiving radiation therapy for cancers in the abdomen or pelvis. About 122 adults will be randomly assigned to receive either the supplement or a placebo. The goal i…
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Can a custom exercise plan boost survival in older women with gynecologic cancers?
Symptom relief Recruiting nowThis study tests a personalized physical activity program for women over 60 with gynecologic cancers who are receiving chemotherapy or other systemic treatments. The program includes a wearable activity tracker and a smartphone app, plus optional features like an exercise partner…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New radiation method aims to reduce side effects in cervical cancer treatment
Symptom relief Recruiting nowThis study tests a newer, more precise type of radiation called SBRT for women with stage IIIC cervical cancer. The goal is to see if it can safely deliver high doses to cancer in the pelvic lymph nodes while causing fewer side effects than standard radiation. About 150 women wil…
Phase: NA • Sponsor: All India Institute of Medical Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Acupuncture needles take on chemo sickness
Symptom relief Recruiting nowThis study tests whether adding acupuncture and acupressure to standard anti-nausea medicine can better reduce chemotherapy-induced nausea. About 90 cancer patients with ongoing nausea will be split into two groups: one gets the extra acupuncture, the other gets medicine alone. T…
Phase: NA • Sponsor: Vejle Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Simple injection may ease pain after hysterectomy surgery
Symptom relief Recruiting nowThis study tests whether injecting the local anesthetic bupivacaine into the small surgical cuts and the vaginal cuff at the end of a laparoscopic hysterectomy can lower postoperative pain. 120 women having the surgery for non-cancer reasons will be randomly assigned to receive t…
Phase: NA • Sponsor: Serkan Kumbasar • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Freeze your pain away? cryotherapy trial for endometriosis launches
Symptom relief Recruiting nowThis study tests if whole-body cryotherapy (standing in a -120°C chamber for 3 minutes) can safely reduce pain and improve quality of life in people with endometriosis. Thirty participants with chronic pelvic pain will attend 5 sessions over 4 weeks. Researchers will measure pain…
Phase: NA • Sponsor: University of Edinburgh • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Yoga vs. endometriosis pain: new study tests a Drug-Free approach
Symptom relief Recruiting nowThis study tests whether a 12-week virtual yoga program can reduce pain in women with endometriosis. Researchers will enroll 30 women aged 18-45 who have moderate pain and a confirmed diagnosis. Participants will attend online yoga classes and report their pain levels using quest…
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New vaginal tablet could ease menopause discomfort
Symptom relief Recruiting nowThis study tests a vaginal tablet called AZU-101 (lasofoxifene) in 90 postmenopausal women aged 45-60 who have vaginal atrophy, causing dryness and pain during sex. The tablet is given daily for 14 days to see if it is safe and can improve vaginal cell health and lower vaginal pH…
Phase: PHASE2 • Sponsor: Azure Biotech Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Could a probiotic boost yeast infection treatment?
Symptom relief Recruiting nowThis study tests whether adding a probiotic supplement (Bioithas WOMAN®) to standard antifungal medicine helps relieve symptoms of vaginal yeast infections faster. About 60 women with suspected yeast infections will take either antifungal treatment alone or with the probiotic for…
Phase: NA • Sponsor: Bioithas SL • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Which surgery works best for rectocele? new trial aims to find out
Symptom relief Recruiting nowThis study compares two surgical methods (through the anus or through the vagina) to treat a condition called rectocele, where the wall between the rectum and vagina weakens, causing constipation and difficulty passing stool. About 62 women who have not improved with other treatm…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New study: Protein-Rich diet and exercise before surgery may help older cancer patients recover faster
Symptom relief Recruiting nowThis study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Could a magnetic device ease endometriosis pain without drugs?
Symptom relief Recruiting nowThis study tests whether pulsed electromagnetic field (PEMF) therapy can reduce pain and improve quality of life in women with endometriosis. Sixty women aged 18–45 will receive either real PEMF or a sham device three times a week for 8 weeks. Researchers will measure pain, pelvi…
Phase: NA • Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New hope for endometriosis pain: exercise and education program shows promise
Symptom relief Recruiting nowThis study tests whether a physiotherapy program that combines gentle exercise with pain education can reduce pain and improve daily life for women with endometriosis. About 62 women will take part, with half receiving the combined program and half receiving pain education alone.…
Phase: NA • Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Biofeedback training aims to restore sexual health in cervical cancer survivors
Symptom relief Recruiting nowThis study tests whether special pelvic floor exercises, guided by a biofeedback device, can improve sexual function in women who had radiation for cervical cancer. Sixty survivors with sexual problems will be randomly assigned to either biofeedback-assisted training or standard …
Phase: NA • Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Fewer hospital visits for cancer radiation? new trial tests shorter treatment
Symptom relief Recruiting nowThis study is testing whether a shorter course of pelvic radiation after surgery works as well as the standard longer schedule for people with cervical or endometrial cancer. The shorter schedule means fewer hospital visits and less time in treatment. About 120 participants will …
Phase: NA • Sponsor: Siriraj Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Could a new scope improve bowel surgery for endometriosis?
Symptom relief Recruiting nowThis study tests a new surgical technique called intra-operative dual laparoscopy and neo-rectoscopy (IDLnR) for treating bowel endometriosis. Researchers will compare it to standard laparoscopic surgery in 192 women aged 18-55. The goal is to see if the new method leads to bette…
Phase: NA • Sponsor: Obstetrics & Gynecology Hospital of Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Podcast therapy: a new hope for pelvic pain sufferers?
Symptom relief Recruiting nowThis study tests whether listening to an educational podcast can improve quality of life, reduce stigma, and increase satisfaction for people with chronic pelvic pain or endometriosis. One hundred participants will either receive standard care or standard care plus access to the …
Phase: NA • Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Cancer care at home: a Game-Changer for patients?
Symptom relief Recruiting nowThis study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Scientists try to personalize heated chemo for stomach cancers
Knowledge-focused Recruiting nowThis study looks at a treatment called HIPEC, where heated chemotherapy is washed inside the abdomen after surgery to remove tumors. Researchers want to see if lab-grown tumor models can predict how well the chemotherapy works. Sixty adults with cancers that have spread to the ab…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New trial uses DNA tests to match cancer patients to targeted drug cocktails
Knowledge-focused Recruiting nowThis large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Researchers launch major tissue bank to unlock secrets of mesothelioma
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Rare cancer syndrome under the microscope: what families need to know
Knowledge-focused Recruiting nowThis study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New online tool aims to ease financial burden for cancer patients
Knowledge-focused Recruiting nowThis study is testing a web-based tool called CARE that gives cancer patients information about treatment costs, health insurance, and financial resources. About 430 adults with gynecologic, prostate, lung, or colorectal cancer will use the tool to see if it helps them feel more …
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New study tests if popping the last membrane gets labour going faster
Knowledge-focused Recruiting nowAbout 1 in 4 women have their water break before labour starts. Most go into labour within 48 hours, but some need to be induced. This study tests whether deliberately breaking the leftover membrane when a woman is admitted to the hospital can shorten the time to labour and reduc…
Phase: NA • Sponsor: Centre Hospitalier le Mans • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Massive study tracks tiny babies to unlock secrets of early development
Knowledge-focused Recruiting nowThis study follows thousands of very low birth-weight and premature infants to track their development over time. Researchers collect data on pregnancy, birth, and early childhood outcomes to identify factors that influence brain and body development. No treatments are tested—thi…
Sponsor: NICHD Neonatal Research Network • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Bacteria in the mouth and gut may predict who responds to cancer immunotherapy
Knowledge-focused Recruiting nowThis study looks at the bacteria living in the mouth, stool, and tumors of Colombian adults with advanced cancers of the stomach, colon, breast, cervix, or head and neck who are starting immunotherapy as standard care. Researchers will compare these microbial profiles to those of…
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Brazilian study maps HER2 in Women's cancers to guide future treatments
Knowledge-focused Recruiting nowThis study will test tumor samples from 350 adults with gynecological cancers (endometrial, ovarian, cervical, vulvar, and vaginal) to see how often they have high levels of the HER2 protein. Researchers will use two standard lab tests to measure HER2. The goal is to learn how co…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Blood test may guide cancer care without biopsy
Knowledge-focused Recruiting nowThis study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…
Phase: NA • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Brazil launches major study to map ovarian cancer treatment gaps
Knowledge-focused Recruiting nowThis observational study will look at how ovarian cancer is currently treated in Brazil, including surgeries, chemotherapy, and genetic testing. Researchers will collect data from 250 patients to find what is working well and what needs improvement. The goal is to use these insig…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Massive cancer database aims to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Live biopsy study aims to predict immunotherapy response in cancer patients
Knowledge-focused Recruiting nowThis study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Can a smartphone app ease the stress of cancer genetic testing?
Knowledge-focused Recruiting nowThis study tests a digital app called the Genetics Adviser for Mainstream Care (GA-Mainstream) that educates cancer patients about genetic testing and delivers their results. Researchers want to see if using the app reduces distress and improves the patient experience compared to…
Phase: NA • Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
UK launches massive endometriosis study to unlock secrets of the painful condition
Knowledge-focused Recruiting nowENDO1000 is a UK-wide research project involving 1000 people with endometriosis. Participants will use a mobile app to track symptoms like pain, fatigue, and sleep, and some will provide blood, urine, and other samples at home. The goal is to collect detailed data over time to he…
Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists hunt for genes behind puberty problems
Knowledge-focused Recruiting nowThis study aims to understand how reproductive disorders, such as delayed or early puberty, are inherited. Researchers will collect blood samples and medical histories from 850 people with these conditions and their family members. No treatment is provided; the goal is to identif…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study creates ovarian tissue databank to unlock fertility secrets
Knowledge-focused Recruiting nowThis study collects and stores ovarian tissue from females aged 4 to 35 who choose to freeze a sample before cancer treatment that could harm their fertility. Researchers will also gather medical data and annual surveys for up to 30 years. The goal is to build a national database…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could low egg count predict miscarriage? new study seeks answers
Knowledge-focused Recruiting nowThis study is looking at whether women with lower ovarian reserve (fewer eggs) have had more early miscarriages in the past. Researchers will measure ovarian reserve with a blood test (AMH) and an ultrasound (antral follicle count) in over 2,000 women seeking fertility care. This…
Sponsor: ART Fertility Clinics LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Measuring follicle volume could improve IVF timing for poor responders
Knowledge-focused Recruiting nowThis study looks at 100 women with very low ovarian reserve (fewer than 4 follicles) undergoing IVF. Researchers will measure the volume of each follicle just before the trigger shot that matures the eggs. They want to see if follicle volume is a better predictor of egg maturity …
Sponsor: ART Fertility Clinics LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could a simple test spot endometriosis sooner?
Knowledge-focused Recruiting nowThis study is looking at 135 women with and without endometriosis to understand how hormones, environmental chemicals, and vaginal bacteria differ between the groups. Researchers hope to find patterns that could lead to faster diagnosis and better treatments. Participants give bl…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Immune clues in the blood may predict IVF success
Knowledge-focused Recruiting nowThis study tracks immune-related substances in the blood of 40 women undergoing a frozen embryo transfer. Researchers want to see how these markers change before and after the transfer, and whether they relate to pregnancy success. The goal is to better understand the role of the…
Sponsor: ART Fertility Clinics LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New registry aims to learn from Real-World retreatment of gynecologic cancers
Knowledge-focused Recruiting nowThis observational registry is gathering data from 500 adults whose gynecologic cancer has returned after prior radiation therapy. Doctors are using reirradiation or other ablative strategies as part of standard care, and the registry will track how well these treatments control …
Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
FSH blood tests during IVF could personalize doses
Knowledge-focused Recruiting nowThis study looks at whether tracking FSH levels during ovarian stimulation can help predict how many eggs a woman will produce. Researchers will monitor 150 women undergoing IVF to find the ideal FSH range for better outcomes. The goal is to tailor hormone doses to each patient, …
Sponsor: ART Fertility Clinics LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could a chatbot help close the gap in genetic cancer testing?
Knowledge-focused Recruiting nowThis study compares a smartphone chatbot to usual care for collecting family history and identifying women at high risk for hereditary cancer syndromes. Participants are English-speaking gynecology patients aged 18 and older who have not had prior genetic testing. The goal is to …
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to keep women with HIV on track for cervical cancer treatment
Knowledge-focused Recruiting nowThis study in South Africa works with women who have HIV and abnormal Pap results to find out why some don't follow up for cervical cancer care. Researchers will interview patients and providers, then create a short counseling and navigation program. They will test if the program…
Phase: NA • Sponsor: Boston University Charles River Campus • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can freezing ovarian tissue help people with turner syndrome or early menopause have kids?
Knowledge-focused Recruiting nowThis study looks at whether freezing ovarian tissue can help preserve fertility in people aged 2-21 with conditions like Turner syndrome, galactosemia, or premature ovarian insufficiency. Participants may have surgery to remove and freeze a gonad, with a small piece used for rese…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Protein clues may predict cervical cancer return
Knowledge-focused Recruiting nowThis study is looking at 180 women with advanced cervical cancer who were treated with radiation and chemotherapy. Researchers want to see if high levels of certain proteins (called IAPs) in the original tumor biopsy can predict whether the cancer will come back within two years.…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to uncover why some women have worse sexual side effects from radiation
Knowledge-focused Recruiting nowThis study is observing 300 women with female sexual organs who are receiving radiotherapy for certain cancers. Researchers want to understand why some patients have more sexual side effects than others. They will track sexual quality of life and look at radiation doses to find p…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New risk model could spare endometrial cancer patients unnecessary surgery
Knowledge-focused Recruiting nowThis study is testing a computer model called ENDORISK that helps doctors predict whether endometrial cancer has spread to lymph nodes. About 735 patients with early-stage endometrial cancer will use the model to guide decisions about lymph node surgery. The goal is to see if the…
Phase: NA • Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Lupus drug may harm ovaries – could a hormone shot help?
Knowledge-focused Recruiting nowThis study surveys women under 40 with lupus who are starting cyclophosphamide, a drug that can damage ovaries and cause infertility. Some received an additional drug called GnRHa to protect their ovaries. Researchers will compare menstrual health and fertility between those who …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Neck mobility study seeks best stretch for stiff necks
Knowledge-focused Recruiting nowThis study compares two manual therapy techniques—seated extension glides and supine downslip glides—to see which better improves neck rotation range of motion. Researchers will enroll 128 healthy adults aged 18-45 with no history of neck pain. The goal is to help physical therap…
Phase: NA • Sponsor: Missouri State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Choice or fixed? study tests how to get better data from young cancer patients
Knowledge-focused Recruiting nowThis study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…
Phase: NA • Sponsor: Eastern Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Question list may empower gynecologic cancer patients in clinic
Knowledge-focused Recruiting nowThis study tests whether giving gynecologic cancer patients a list of questions to ask their doctor improves their confidence, reduces distress, and builds trust. About 70 adults with newly diagnosed or suspected gynecologic cancer will either receive the question list or usual c…
Phase: NA • Sponsor: Ira Winer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a Hope-Focused workshop ease burnout for ovarian cancer clinicians?
Knowledge-focused Recruiting nowThis study tests a workshop called HOPE-C, designed to reduce burnout among doctors, nurses, and social workers who care for ovarian cancer patients. The workshop helps clinicians share their challenging stories and build peer support. Researchers will enroll 25 participants to s…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test aims to spot hidden cancer cells in 9 tumor types
Knowledge-focused Recruiting nowThis study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
AI chatbot could guide cancer patients through confusing health info
Knowledge-focused Recruiting nowThis study looks at how people with endometrial cancer find medical information and how satisfied they are with it. Researchers will also ask patients if they'd be interested in using an AI-powered educational tool. The goal is to understand current needs and see if AI could help…
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could sleep and diet boost fertility? major study investigates
Knowledge-focused Recruiting nowThis study follows women aged 18 to 44 who are trying to conceive at a fertility clinic. Researchers want to learn how lifestyle habits like sleep, nutrition, and physical activity before pregnancy affect the chances of having a baby. Participants will be followed for up to 25 ye…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists hunt for hidden causes of poor fetal growth
Knowledge-focused Recruiting nowThis study looks at why some babies grow poorly early in pregnancy for no known reason. Researchers will measure a key hormone (progesterone) in the mother's blood and examine a protective protein in the placenta after birth. By comparing 58 pregnancies, they hope to uncover clue…
Sponsor: National University of Malaysia • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
HER2 test showdown: which lab method is best for chinese cancer patients?
Knowledge-focused Recruiting nowThis study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Period power: study seeks to tame blood sugar swings in type 1 diabetes
Knowledge-focused Recruiting nowThis study looks at how menstrual cycles and birth control pills impact blood sugar levels and exercise in women with type 1 diabetes. Researchers will monitor 150 women for three months using continuous glucose monitors and offer personalized insulin and diet adjustments. The go…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Keyhole surgery vs. open surgery: which is better for endometrial cancer in Low-Resource settings?
Knowledge-focused Recruiting nowThis study looks at two surgical methods for early-stage endometrial cancer: laparoscopy (keyhole surgery) and laparotomy (open surgery). It aims to see which one helps patients recover faster, especially in places with limited medical resources. About 48 women will take part, an…
Phase: NA • Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
New study to reveal if EDS worsens menstrual pain
Knowledge-focused Recruiting nowThis study looks at whether women with Ehlers-Danlos syndrome (EDS) experience more severe period pain than those without the condition. Researchers will compare pain levels and other gynecological issues in 156 women using an online questionnaire. The goal is to better understan…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
500 cancer patients join quest to unlock precision medicine secrets
Knowledge-focused Recruiting nowThis study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New imaging study aims to unlock secrets of poor fetal growth
Knowledge-focused Recruiting nowThis study follows 200 babies diagnosed with poor growth in the womb (IUGR) using advanced ultrasound and MRI scans. Researchers want to understand how the baby's brain, heart, and placenta change over time. The goal is to link these changes to the child's development after birth…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Scientists hunt for clues to pre-eclampsia in placenta and blood samples
Knowledge-focused Recruiting nowThis study aims to better understand pre-eclampsia and intrauterine growth restriction (IUGR), serious pregnancy complications affecting about 9% of pregnancies. Researchers will collect placenta, blood, and urine samples from 500 pregnant women—both with and without these condit…
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Can online training boost exercise advice from doctors?
Knowledge-focused Recruiting nowThis study tests an online training program designed to help primary health care workers in Brazil give better advice on physical activity and reducing sedentary time. Over 3,300 health professionals will take the self-paced course and have their counseling skills measured before…
Phase: NA • Sponsor: Universidade Federal do Paraná • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Stress and your cycle: new study investigates the link
Knowledge-focused Recruiting nowThis study looks at how non-food-related stressors (like work or emotional stress) affect menstrual health in pre-menopausal women. Researchers will measure stress hormones and sex hormones in 600 women over 6 months. The goal is to understand if stress directly causes menstrual …
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Hidden trauma: new study reveals psychological toll of cervical cancer radiation
Knowledge-focused Recruiting nowThis study follows 80 cervical cancer patients who receive brachytherapy (internal radiation) to see if they develop post-traumatic stress disorder (PTSD). Participants fill out questionnaires about PTSD, anxiety, depression, quality of life, and sexual health over 5 years. The g…
Sponsor: Centre Paul Strauss • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New scan may reveal hidden estrogen activity in uterine cancer
Knowledge-focused Recruiting nowThis study is testing a special PET scan (FES PET/CT) to see how active estrogen receptors are in uterine cancer that has spread or returned. About 30 women with this type of cancer will get the scan before starting a new treatment. The results won't change their treatment plan b…
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
10,000 cancer patients join ontario Gene-Mapping effort to personalize care
Knowledge-focused Recruiting nowThis study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Could saving a tiny artery prevent deadly leaks after colon surgery?
Knowledge-focused Recruiting nowThis study looks at whether preserving the left colic artery during colon or rectal cancer surgery helps keep the remaining colon well-supplied with blood. Surgeons will temporarily clamp the main artery and use a green dye to measure blood flow. The goal is to see if this techni…
Phase: NA • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study gathers key materials to create personalized cell therapies for tough cancers
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Robot-Assisted GYN surgery under the microscope: new study tracks Real-World outcomes
Knowledge-focused Recruiting nowThis study is observing how well robotic-assisted surgery works for women with gynecological conditions. It will follow 1,250 participants in Germany for up to 12 months after surgery to track complications, recovery, and patient-reported outcomes. The goal is to gather real-worl…
Sponsor: Intuitive Surgical • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Could skipping breakfast help fight uterine cancer?
Knowledge-focused Recruiting nowThis study looks at whether it is safe for women with endometrial cancer to fast overnight before their surgery. Many women with this cancer have high blood sugar and inflammation, which may help the cancer grow. The study will check if fasting is doable and liked by patients, an…
Phase: NA • Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists launch Long-Term study to unravel mysterious liver disease
Knowledge-focused Recruiting nowThis study is observing 400 people aged 12 and older who have noncirrhotic portal hypertension (NCPH) or are at risk for it. NCPH is a liver condition that increases blood pressure in the liver's blood vessels without causing cirrhosis, and often has no early symptoms. Researcher…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Which surgery is better for uterine septum? new trial aims to find out
Knowledge-focused Recruiting nowThis study compares two surgical techniques for removing a uterine septum—a wall of tissue inside the uterus that can cause pregnancy complications. One method uses scissors without electricity, while the other uses a heated wire. Researchers will track surgery time, costs, and r…
Phase: NA • Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
500 women with advanced uterine cancer to have tumors genetically profiled
Knowledge-focused Recruiting nowThis study looks at the genetic makeup of advanced endometrial cancer in 500 women in Russia. Researchers will test tumor samples for specific gene changes to see how common they are and what treatments patients receive. The goal is to gather information, not to test a new treatm…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Major study launches to unravel mysteries of early menopause
Knowledge-focused Recruiting nowThis study follows 1080 women diagnosed with premature ovarian insufficiency (POI) before age 40. Researchers will track their health over time, including bone density, hormone levels, and mental well-being. The goal is to identify risk factors and understand how POI affects over…
Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Friends and fitness: key to life after cancer?
Knowledge-focused Recruiting nowThis study follows 250 young adult cancer survivors to see how their social relationships and physical activity change over time and how these factors affect their quality of life. Participants wear an activity tracker and complete surveys. The goal is to learn how to better supp…
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Bolivia study to uncover hidden risks of High-Altitude pregnancy
Knowledge-focused Recruiting nowThis study follows 27 pregnant women living at high altitude in Bolivia and compares them to women at sea level. Researchers will use heart ultrasounds and blood tests to see how the body adapts to low oxygen levels during pregnancy. The goal is to better understand why some wome…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Rural women get boost in cancer genetic screening trial
Knowledge-focused Recruiting nowThis study looks at whether a family history screening program can help more women in rural public health clinics get tested for genetic risks linked to breast and ovarian cancer. About 3,200 women over age 25 will take part. The goal is to see if the program increases the number…
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Can a Week-Long wellness retreat boost cancer recovery?
Knowledge-focused Recruiting nowThis pilot study is testing whether a 7-day integrative oncology retreat called 'Via Shalva' is practical and helpful for women who have finished primary treatment for breast or gynecologic cancer. Thirty participants will either attend the retreat or receive usual follow-up care…
Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New study tracks ovarian cancer care in real life
Knowledge-focused Recruiting nowThis study follows 750 women with advanced ovarian cancer in Germany to see how they are treated in real-world settings. It focuses on the use of PARP inhibitor maintenance therapy after chemotherapy and how it affects outcomes and quality of life. The goal is to learn what works…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Cancer vans bring genetic testing to women who need it most
Knowledge-focused Recruiting nowThis study aims to find women in Texas who are at risk for hereditary breast, ovarian, and colorectal cancers but have limited access to healthcare. Researchers will use mobile mammography units to offer genetic testing and counseling on the spot. Up to 1,000 women will provide a…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Can some endometrial cancer patients skip lymph node surgery?
Knowledge-focused Recruiting nowThis observational study is looking at 350 women with early-stage endometrial cancer to see if doctors can better predict who really needs lymph node removal during surgery. Participants receive standard care and are followed for three years. The goal is to find out if some patie…
Sponsor: University Hospital Hradec Kralove • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Can a video replace genetic counseling for cancer patients?
Knowledge-focused Recruiting nowThis study is testing whether an 8-minute educational video can effectively prepare cancer patients for genetic testing, compared to standard genetic counseling. Over 1,000 adults with various cancers will participate. The goal is to see if the video is acceptable and improves un…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New ultrasound tech could spot hidden placental problems in pregnancy
Knowledge-focused Recruiting nowThis study is testing two new ultrasound techniques to see if they can tell the difference between healthy pregnancies and those affected by fetal growth restriction (FGR), where the baby is smaller than expected. Researchers will scan 60 pregnant women every three weeks using a …
Phase: NA • Sponsor: Carilion Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New tool aims to make cancer treatment safer for seniors
Knowledge-focused Recruiting nowThis study tests a new tool called TRTRM that predicts which older cancer patients are at high risk for severe side effects from treatment. Researchers will use the tool to adjust drug doses and monitoring for patients aged 65 and older with solid tumors. The goal is to see if th…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Can talking to others fight cancer loneliness?
Knowledge-focused Recruiting nowThis study looks at whether joining a support group can improve emotional well-being and reduce feelings of isolation for people with a rare cervical cancer called NECC. About 40 adults with NECC will take part. Researchers will use surveys to measure changes in how participants …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
BRCA study aims to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects tumor and blood samples from 3,300 people at high genetic risk for breast, ovarian, and related cancers. Researchers want to learn how these cancers develop and how well treatments work. Participants include those with BRCA1/2 or other gene mutations, or a str…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Microchip implanted in tumors could personalize ovarian cancer treatment
Knowledge-focused Recruiting nowThis early-stage study tests a small implantable device that is placed directly into tumors to see how different drugs work against ovarian, fallopian tube, and peritoneal cancers. About 20 people with advanced cancer will receive the device during standard surgery. The goal is t…
Phase: PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC